ALDVI — Advicenne SA Share News
0.000.00%
Last trade - 00:00- €15.83m
- €33.49m
- €6.01m
Brief: Advicenne Announces Commercialization Agreement With Taiba For Sibnayal In Middle East
Brief: Advicenne Appoints Philippe Boucheron As Chairman
Brief: Advicenne Announces Partly Recovery From Growth Retardation After Control Of Metabolic Acidosis With ADV-7103
Brief: Advicenne End-Dec Closing Cash Position At 12.7 Million Euros
Brief: Advicenne Announces Results Of A Study Showing Improved Quality Of Life in Patients Treated With ADV7103
Brief: Advicenne Shareholders Approve Listing Transfer To Euronext Growth
Brief: Advicenne 2021 Sales Up 20% To 3.3 Million Euros
Brief: Advicenne announces commercialization agreement with FrostPharma AB for Sibnayal™ in the Nordic region
Brief: Advicenne: Commercialization Agreement With FrostPharma For Sibnayal
Brief: Advicenne Announces Positive Opinion From French Transparency Commission For Its Drug Sibnayal In dRTA
Brief: Advicenne Completes First Round Of UK Pricing Negotiations For Sibnayal, Signs Two Exclusive Distribution Agreements in EU
Brief: Advicenne Proposal To Transfer Shares From Euronext Brussels To Euronext Growth Paris
Brief: Advicenne H1 Net Loss Widens To 8.0 Million Euros
Brief: Advicenne Wins UK Approval To Market Sibnayal For dRTA
Brief: Advicenne Raises Around 9.4 Million Euros In Private Placement
Brief: Advicenne Launches Capital Increase Of Around EUR 10 Mln
Brief: Advicenne Expects Marketing Authorisation In U.S On Sibnayal By End-2022
Brief: Advicenne To Resume Phase III Trial Of ADV7103 In USA In June
Brief: Advicenne Names New CEO While EC Approves Marketing Of ADV7103